Athira Pharma, Inc. (NASDAQ:ATHA) Sees Significant Drop in Short Interest

Athira Pharma, Inc. (NASDAQ:ATHA) was the recipient of a significant decrease in short interest in January. As of January 31st, there was short interest totalling 949,500 shares, a decrease of 30.7% from the January 15th total of 1,370,000 shares. Currently, 2.7% of the shares of the stock are sold short. Based on an average daily volume of 443,300 shares, the short-interest ratio is presently 2.1 days.

Athira Pharma Price Performance

Shares of NASDAQ ATHA opened at $0.47 on Friday. Athira Pharma has a 52-week low of $0.41 and a 52-week high of $4.30. The business has a fifty day moving average of $0.54 and a two-hundred day moving average of $1.01.

Institutional Trading of Athira Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bristlecone Advisors LLC raised its holdings in Athira Pharma by 295.6% in the third quarter. Bristlecone Advisors LLC now owns 337,506 shares of the company’s stock worth $151,000 after purchasing an additional 252,200 shares during the period. GSA Capital Partners LLP raised its stake in shares of Athira Pharma by 909.8% in the 3rd quarter. GSA Capital Partners LLP now owns 397,111 shares of the company’s stock valued at $177,000 after purchasing an additional 357,787 shares during the period. Finally, BML Capital Management LLC bought a new stake in shares of Athira Pharma in the fourth quarter valued at about $1,629,000. 57.12% of the stock is owned by institutional investors.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.